Premium
The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
Author(s) -
elRaghy I.,
Back DJ,
Osman F.,
Nafeh MA,
Orme ML
Publication year - 1985
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1985.tb05069.x
Subject(s) - schistosomiasis , ascites , pharmacokinetics , gastroenterology , medicine , liver biopsy , volume of distribution , urine , microsome , biopsy , immunology , biology , helminths , biochemistry , enzyme
The pharmacokinetics of antipyrine have been studied in patients with schistosomiasis. In comparison to a control group of subjects (n = 6), patients with early (active) schistosomiasis (passing live ova in urine or stools without clinical and laboratory evidence of liver involvement; n = 6) exhibited similar pharmacokinetic parameters. Of seven patients with hepatosplenic schistosomiasis (exhibiting hepatic fibrosis, splenomegaly, at least one episode of haematemesis, ascites), five showed markedly enhanced antipyrine half‐life and reduced clearance. Compared to controls, the mean half‐life of this group was increased from 10.9 +/‐ 2.4 to 19.9 +/‐ 9.5 h (mean +/‐ s.d.; P less than or equal to 0.05) and clearance reduced from 3.81 +/‐ 0.74 to 2.18 +/‐ 0.80 l h‐1 (P less than or equal to 0.01). There was no change in the apparent volume of distribution. Liver biopsy was performed on all patients diagnosed as having hepatosplenic schistosomiasis in the 2 weeks prior to the antipyrine study. The results of this study indicate that hepatic microsomal metabolism is impaired in patients with advanced hepatosplenic schistosomiasis.